Episode 1 is a venture capital fund formed by experienced entrepreneurs and operators that invests in early stage business to business software companies.
GV led the seed financing round to support team expansion and technology development.
"Access to the law should be a basic right, available to everyone. Unfortunately this isn’t the case. Our vision is to combine AI and best-in-class lawyers to reduce the time and cost of providing high-quality legal support, increasing access for millions of people who need it."
The seed round was led by Episode 1 with participation from Playfair Capital, Portfolio Ventures, and others.
"In less than a year, Romain and Guillaume have built a differentiated product that is loved by its users. Their best-in-class security and real-time architecture means they can serve entire categories their competitors cannot. They are rapidly becoming the default option for privacy conscious tech teams looking to scale integrations. We couldn’t be more delighted to back this team to disrupt the integrations market."
The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.
"We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need"
Episode 1 led the pre-seed round to help the platform expand its team and accelerate product development.
"Generative AI is poised to be a multi-trillion dollar industry, and Sentify’s unique approach to LLM analytics positions it as a standout solution for businesses looking to leverage the benefits of LLM to provide actionable data. We are pleased to be supporting them on this journey and look forward to their public launch in the coming months."
Plural led the Series A follow-on round to help the company scale its precision medicine platform and expand globally.
"Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural."
